Suppr超能文献

瘦型非酒精性脂肪性肝病:一种未被充分认识的异常情况。

Lean NAFLD: An Underrecognized Outlier.

作者信息

Wattacheril Julia, Sanyal Arun J

机构信息

Center for Liver Disease and Transplantation, Columbia University Medical Center - New York Presbyterian Hospital.

Virginia Commonwealth University, VCU Medical Center.

出版信息

Curr Hepatol Rep. 2016 Jun;15(2):134-139. doi: 10.1007/s11901-016-0302-1. Epub 2016 Apr 14.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is commonly diagnosed in obese or overweight individuals. However, lean individuals with NAFLD are not rare but represent one significant end of the phenotypic spectrum of NAFLD. Although initial observations between obese and lean NAFLD reveal some metabolic parallels, these associations vary widely given differences in study populations and metabolic parameters assessed. The role of body composition in risk assessment is significant and incompletely assessed during most clinical encounters. Recent multinational investigation reveals an increased mortality in lean individuals with NASH. Many aspects of lean NAFLD need further exploration including epidemiology, clinical risk assessment, histologic changes unique to lean NAFLD, genetic and pathophysiologic mechanisms predisposing at risk individuals, natural history and treatment strategies in this underrecognized population.

摘要

非酒精性脂肪性肝病(NAFLD)常见于肥胖或超重个体。然而,患有NAFLD的瘦人并不罕见,而是代表了NAFLD表型谱的一个重要端点。尽管肥胖和瘦型NAFLD之间的初步观察揭示了一些代谢方面的相似之处,但由于研究人群和评估的代谢参数存在差异,这些关联差异很大。在大多数临床诊疗过程中,身体组成在风险评估中的作用重大但未得到充分评估。最近的跨国调查显示,患有非酒精性脂肪性肝炎(NASH)的瘦人死亡率增加。瘦型NAFLD的许多方面都需要进一步探索,包括流行病学、临床风险评估、瘦型NAFLD特有的组织学变化、使高危个体易患的遗传和病理生理机制、这个未得到充分认识的人群的自然史和治疗策略。

相似文献

1
Lean NAFLD: An Underrecognized Outlier.
Curr Hepatol Rep. 2016 Jun;15(2):134-139. doi: 10.1007/s11901-016-0302-1. Epub 2016 Apr 14.
2
Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
Clin Gastroenterol Hepatol. 2017 Oct;15(10):1604-1611.e1. doi: 10.1016/j.cgh.2017.04.045. Epub 2017 May 26.
3
Differential Mortality Outcomes in Real-world Patients with Lean, Nonobese, and Obese Nonalcoholic Fatty Liver Disease.
J Clin Transl Hepatol. 2023 Dec 28;11(7):1448-1454. doi: 10.14218/JCTH.2023.00016. Epub 2023 Nov 27.
4
Pathology of nonalcoholic steatohepatitis.
Hepatol Res. 2005 Oct;33(2):68-71. doi: 10.1016/j.hepres.2005.09.006. Epub 2005 Oct 7.
7
Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels.
Scand J Gastroenterol. 2015 Mar;50(3):341-6. doi: 10.3109/00365521.2014.983160. Epub 2014 Dec 26.
8
Non-alcoholic Fatty Liver Disease in Lean Subjects: Characteristics and Implications.
J Clin Transl Hepatol. 2017 Sep 28;5(3):216-223. doi: 10.14218/JCTH.2016.00068. Epub 2017 Jul 5.
9
NAFLD in normal weight individuals.
Diabetol Metab Syndr. 2022 Mar 24;14(1):45. doi: 10.1186/s13098-022-00814-z.
10
Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
Am J Physiol Gastrointest Liver Physiol. 2019 Apr 1;316(4):G462-G472. doi: 10.1152/ajpgi.00358.2018. Epub 2019 Jan 17.

引用本文的文献

1
Beyond BMI: revealing metabolic risk in lean MASLD.
Arch Clin Cases. 2025 Aug 4;12(3):110-118. doi: 10.22551/2025.48.1203.10322. eCollection 2025.
2
Non-alcoholic fatty liver disease development: A multifactorial pathogenic phenomena.
Liver Res. 2022 May 19;6(2):72-83. doi: 10.1016/j.livres.2022.05.002. eCollection 2022 Jun.
3
Metabolic dysfunction associated fatty liver disease in healthy weight individuals.
Hepatol Int. 2024 Oct;18(Suppl 2):884-896. doi: 10.1007/s12072-024-10662-w. Epub 2024 Jul 25.
4
Non-invasive hepatic fat quantification: Can multi-echo Dixon help?
Radiol Bras. 2024 May 7;57:e20230125. doi: 10.1590/0100-3984.2023.0125. eCollection 2024 Jan-Dec.
7
Non-alcoholic Steatohepatitis in Asians: Current Perspectives and Future Directions.
Cureus. 2023 Aug 2;15(8):e42852. doi: 10.7759/cureus.42852. eCollection 2023 Aug.
8
Metabolic and Risk Profiles of Lean and Non-Lean Hepatic Steatosis among US Adults.
Nutrients. 2023 Jun 23;15(13):2856. doi: 10.3390/nu15132856.
10
The bidirectional impacts of alcohol consumption and MAFLD for progressive fatty liver disease.
Ther Adv Endocrinol Metab. 2023 Jun 5;14:20420188231178370. doi: 10.1177/20420188231178370. eCollection 2023.

本文引用的文献

1
Adipose tissue and metabolic syndrome: too much, too little or neither.
Eur J Clin Invest. 2015 Nov;45(11):1209-17. doi: 10.1111/eci.12519. Epub 2015 Sep 13.
2
Lean NASH: distinctiveness and clinical implication.
Hepatol Int. 2013 Dec;7 Suppl 2:806-13. doi: 10.1007/s12072-013-9477-5. Epub 2013 Oct 17.
3
Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population.
World J Gastroenterol. 2014 Dec 21;20(47):17932-40. doi: 10.3748/wjg.v20.i47.17932.
4
Biology of upper-body and lower-body adipose tissue--link to whole-body phenotypes.
Nat Rev Endocrinol. 2015 Feb;11(2):90-100. doi: 10.1038/nrendo.2014.185. Epub 2014 Nov 4.
6
Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011-2012.
J Gastroenterol. 2015 Jan;50(1):95-108. doi: 10.1007/s00535-014-0948-9. Epub 2014 Mar 12.
8
Nonalcoholic fatty liver disease in lean individuals in the United States.
Medicine (Baltimore). 2012 Nov;91(6):319-327. doi: 10.1097/MD.0b013e3182779d49.
10
Associations of visceral and liver fat with the metabolic syndrome across the spectrum of obesity: the AGES-Reykjavik study.
Obesity (Silver Spring). 2011 Jun;19(6):1265-71. doi: 10.1038/oby.2010.291. Epub 2010 Dec 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验